Journal
ONCOTARGET
Volume 6, Issue 11, Pages 8822-8838Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.3558
Keywords
Lmdd-MPFG; Hepatocellular carcinoma; dendritic cells; PRRs
Categories
Funding
- National Natural Science Foundation [30901750, 81272322, 81072029]
- National Basic Research Program of China [2012CB910800]
- Natural Science Foundation of Jiangsu Province [BK2010532]
- China Postdoctoral Science Foundation [20090461133]
- Jiangsu Planned Projects for Postdoctoral Research Funds [1001028B]
- Jiangsu Province Laboratory of Pathogen Biology [11BYKF02]
- Jiangsu Science and Technology Innovation Program for Graduate Research Funds [CXLX13-54]
- Qing Lan Project
- Student Innovation Training Program
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Ask authors/readers for more resources
Immunotherapy is a promising treatment for liver cancer. Here, we tested the ability of the attenuated hepatocellular carcinoma-specific Listeria vaccine (Lmdd-MPFG) to treat hepatocellular carcinoma (HCC) in a mouse model. Immunization with the vaccine caused a strong anti-tumor response, especially in mice reinfused with dendritic cells (DCs). In mice that were also administered DCs, tumor suppression was accompanied by the strongest cytotoxic T lymphocyte response of all treatment groups and by induced differentiation of CD4+T cells, especially Th17 cells. Additionally, the Lmdd-MPFG vaccine caused maturation of DCs in vitro. We demonstrated the synergistic effect of TLR4 and NLRP3 or NOD1 signaling pathways in LM-induced DC activation. These results suggest that the Lmdd-MPFG vaccine is a feasible strategy for preventing HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available